Nanoparticulate alternatives for drug delivery

James H. Adair; Mylisa P. Parette; Erhan I. Altinoǧlu; Mark Kester

doi:10.1021/nn102324e

Nanoparticulate alternatives for drug delivery

James H. Adair, Mylisa P. Parette, Erhan I. Altinoǧlu, Mark Kester

Research output: Contribution to journal › Article › peer-review

206 Scopus citations

Abstract

The ability to apply nanomaterials as targeted delivery agents for drugs and other therapeutics holds promise for a wide variety of diseases, including many types of cancer. A nanodelivery vehicle must demonstrate in vivo efficacy, diminished or no toxicity, stability, improved pharmacokinetics, and controlled-release kinetics. In this issue, Lee et al.construct polymer nanobins that fulfill these requirements and demonstrate effective delivery of doxorubicin in vivo to breast cancer cells. This Perspective explores the outlook for these nanobins as well as other technologies in this field and the challenges that lie ahead.

Original language	English (US)
Pages (from-to)	4967-4970
Number of pages	4
Journal	ACS nano
Volume	4
Issue number	9
DOIs	https://doi.org/10.1021/nn102324e
State	Published - Sep 28 2010

All Science Journal Classification (ASJC) codes

General Materials Science
General Engineering
General Physics and Astronomy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/nn102324e

Cite this

@article{91905ed548134b519ba7402f9832320c,

title = "Nanoparticulate alternatives for drug delivery",

abstract = "The ability to apply nanomaterials as targeted delivery agents for drugs and other therapeutics holds promise for a wide variety of diseases, including many types of cancer. A nanodelivery vehicle must demonstrate in vivo efficacy, diminished or no toxicity, stability, improved pharmacokinetics, and controlled-release kinetics. In this issue, Lee et al.construct polymer nanobins that fulfill these requirements and demonstrate effective delivery of doxorubicin in vivo to breast cancer cells. This Perspective explores the outlook for these nanobins as well as other technologies in this field and the challenges that lie ahead.",

author = "Adair, {James H.} and Parette, {Mylisa P.} and Altinoǧlu, {Erhan I.} and Mark Kester",

year = "2010",

month = sep,

day = "28",

doi = "10.1021/nn102324e",

language = "English (US)",

volume = "4",

pages = "4967--4970",

journal = "ACS nano",

issn = "1936-0851",

publisher = "American Chemical Society",

number = "9",

}

TY - JOUR

T1 - Nanoparticulate alternatives for drug delivery

AU - Adair, James H.

AU - Parette, Mylisa P.

AU - Altinoǧlu, Erhan I.

AU - Kester, Mark

PY - 2010/9/28

Y1 - 2010/9/28

N2 - The ability to apply nanomaterials as targeted delivery agents for drugs and other therapeutics holds promise for a wide variety of diseases, including many types of cancer. A nanodelivery vehicle must demonstrate in vivo efficacy, diminished or no toxicity, stability, improved pharmacokinetics, and controlled-release kinetics. In this issue, Lee et al.construct polymer nanobins that fulfill these requirements and demonstrate effective delivery of doxorubicin in vivo to breast cancer cells. This Perspective explores the outlook for these nanobins as well as other technologies in this field and the challenges that lie ahead.

AB - The ability to apply nanomaterials as targeted delivery agents for drugs and other therapeutics holds promise for a wide variety of diseases, including many types of cancer. A nanodelivery vehicle must demonstrate in vivo efficacy, diminished or no toxicity, stability, improved pharmacokinetics, and controlled-release kinetics. In this issue, Lee et al.construct polymer nanobins that fulfill these requirements and demonstrate effective delivery of doxorubicin in vivo to breast cancer cells. This Perspective explores the outlook for these nanobins as well as other technologies in this field and the challenges that lie ahead.

UR - http://www.scopus.com/inward/record.url?scp=77957297345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957297345&partnerID=8YFLogxK

U2 - 10.1021/nn102324e

DO - 10.1021/nn102324e

M3 - Article

C2 - 20873786

AN - SCOPUS:77957297345

SN - 1936-0851

VL - 4

SP - 4967

EP - 4970

JO - ACS nano

JF - ACS nano

IS - 9

ER -

Nanoparticulate alternatives for drug delivery

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this